Docefrez (docetaxel) may be a cancer medication that interferes with the expansion and unfold of cancer cells within the body.
Docefrez is employed to treat carcinoma, non-small cell carcinoma, and adenocarcinoma.
Docefrez may be used for functions unlisted during this medication guide.
Submit your review
Get emergency medical help if you have signs of an allergic reaction to Docefrez: hives, red skin rash; difficult breathing; feeling like you might pass out; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
sudden vision problems;
extreme weakness, severe vomiting or diarrhea;
redness or peeling of the skin on your hands and feet;
numbness, burning pain, or tingly feeling;
a feeling of being drunk - confusion, stumbling, extreme drowsiness;
signs of infection - fever, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing;
low red blood cells - pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
low platelets in your blood - easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
fluid retention - little or no urinating, swelling of your ankles or feet, rapid weight gain; or
liver problems - upper stomach pain, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Older adults may be more likely to have side effects from this medicine.
Common Docefrez side effects may include:
altered sense of taste;
nausea, vomiting, loss of appetite;
temporary hair loss;
mild skin rash; or
fingernail or toenail changes.
Prostate Cancer For hormone-refractory metastatic prostate cancer, the recommended dose of DOCEFREZ is 75 mg/m2 every 3 weeks as a 1 hour intravenous infusion. Prednisone 5 mg orally twice daily is administered continuously. Breast Cancer: For locally advanced or metastatic breast cancer after failure of prior chemotherapy, the recommended dose of DOCEFREZ is 60 mg/m2 to 100 mg/m2 administered intravenously over 1 hour every 3 weeks.